Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Agenus Inc. (AGEN) Shareholders

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy products, botensilimab and balstilimab, which were overstated [2] - It is alleged that the clinical results and regulatory prospects of these products were misrepresented, leading to materially false and misleading public statements [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request appointment as lead plaintiff, although participation in any recovery does not require this [2] - Class members may be entitled to compensation without any out-of-pocket costs or fees [2] Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3] - The firm has over 70 employees dedicated to serving clients in complex securities litigation [3]